Table 2.

Adjusted analysis for OS in first-line therapy and in treatment sequences

Effect	Hazard ratio	95% CI	P value
In 1L therapy
1L therapy FFX vs. nab-P + G	0.99	(0.74, 1.34)	0.96
Age at therapy initiation (years)	1.00	(0.99, 1.02)	0.57
Gender male vs. female	1.17	(0.85, 1.61)	0.33
Number of comorbidities	1.16	(1.06, 1.28)	< 0.01*
Number of metastatic locations	1.23	(1.04, 1.44)	< 0.05*
Duration of MPAC at therapy initiation (months)	0.99	(0.99, 1.00)	0.15
ECOG vs. score 0
Score 1	1.17	(0.77, 1.78)	0.45
Score 2	1.44	(0.87, 2.37)	0.16
Score 3–4	1.19	(0.51, 2.78)	0.68
In treatment sequences
Treatment sequence (active 2L) FFX → active 2L vs. nab-P + G → active 2L	1.04	(0.79, 1.37)	0.76
Age at therapy initiation (years)	1.02	(1.00, 1.03)	< 0.01*
Gender male vs. female	1.15	(0.86, 1.54)	0.34
Number of comorbidities	0.97	(0.88, 1.07)	0.54
Number of metastatic locations	1.23	(1.07, 1.41)	< 0.01*
Duration of MPAC at therapy initiation (months)	1.00	(0.99, 1.01)	0.97
ECOG vs. score 0
Score 1	1.39	(0.93, 2.08)	0.11
Score 2	1.29	(0.79, 2.12)	0.31
Score 3–4	2.92	(1.42, 6.00)	< 0.01*

CI confidence interval, 1L first-line, 2L second-line, nab-P + G nanoparticle albumin-bound paclitaxel/gemcitabine, FFX FOLFIRINOX, MPAC metastatic adenocarcinoma of the pancreas, ECOG Eastern Cooperative Oncology Group performance status

*P < 0.05